Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared

BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchis

The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in B

BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to p

US stock futures mixed, Intuit shares dip 11.7% after reporting Q4 revenue of $4.35B and adjusted ea

ADAR1 Capital Management LLC bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) dur

— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX - Get Free Report) have received a consensus

Bank of America Corp DE boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 231.6%

Assenagon Asset Management S.A. boosted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX

The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical re

Investors need to pay close attention to BCRX stock based on the movements in the options market lat

BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based r

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and

Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals NASDAQ: BCRX reported second-quarter results marked by growth in ORLADEYO r

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.3 per share, beating the Zack

BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to

— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating pro

ADAR1 Capital Management LLC boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDA

RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd

RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd

The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical re

JP Morgan analyst Jessica Fye reinstates BioCryst Pharma (NASDAQ:BCRX) with a Neutral and announc

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and

HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy

Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana

Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overwei

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today ann

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven ab

Studies highlight the significant healthcare and quality-of-life burden associated with hereditary a

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and rec

Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperfo

Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the

BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.14 per share which beat the analyst

— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibar

PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global

BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.06 per share which beat the analyst

BioCryst Pharma (NASDAQ:BCRX) reported quarterly sales of $163.284 million which beat the analyst co

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abs

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and